1 Unresectable pancreatic cancer is almost universally lethal because 2 chemotherapy and radiation cannot completely stop the growth of the cancer. 3
Introduction 3
The major limiting factor in delivering the appropriate tumoricidal dose of 4 radiation is normal tissue toxicity to adjacent organs 1 . This issue is highlighted 5 by solid tumors of the abdomen and pelvis, such as pancreatic and prostate 6 adenocarcinoma, which often cannot achieve tumoricidal doses without 7 significant morbidity to the gastrointestinal (GI) tract. For instance, pancreatic 8 cancer often occurs in the head of the pancreas, which shares a blood supply 9 with the duodenum, a very radiosensitive portion of the intestinal tract. Tumors 10 of the pancreatic head require doses that exceed 777Gy to achieve local control 2 11 which is often impossible to administer safely because the adjacent duodenum 12 can only tolerate a maximum of 50Gy without causing bleeding ulcers or 13 perforation 3,4 . Unfortunately for patients with unresectable pancreatic cancer, 14 there are no effective treatments that specifically protect the GI tract from this 15 radiotoxicity, and thus ablative radiotherapy is not currently possible. 16 WR-2721 (S-2-[3-aminopropylamino]-ethylphosphorothioic acid), also 17 known as amifostine, is a proven radioprotector of normal tissues and is FDA-18 approved for intravenous administration. When given intravenously, amifostine 19 causes severe nausea and hypotension 5 , which has caused the drug to fall out of 20 favor. WR-2721 exists as a prodrug that is hydrolyzed to the active 21 cytoprotective free thiol metabolite, WR-1065 6 by non-specific tissue alkaline 22 phosphatases that are enriched in normal tissues 7 . Unfortunately these 23 ubiquitous cellular enzymes present in the endothelium may mediate undesirable 1 side effects in the autonomic nervous system 8 . 2 WR-2721 was not formulated for oral delivery due to significant enteral 3 metabolism, which would preclude therapeutic levels from accumulating in the 4 serum and reaching the target organs such as the salivary glands 9 . The entire 5
intestinal tract is enriched with intestinal alkaline phosphatases, which exhibit the 6 highest levels of expression in the duodenum and jejunum 10 . Thus, we reasoned 7 that a dose of WR-2721 given orally just before radiation could be rapidly 8 activated by the endogenous digestive enzymes in the duodenum and jejunum to 9 its active WR-1065 metabolite. This enterally-activated form of WR-2721 would 10 accumulate in high concentrations in the intestines an provide localized 11 radioprotection with potentially fewer systemic side effects. This could be 12 particularly useful during radiation for pancreatic cancer, since the duodenum 13 and jejunum are dose-limiting organs preventing ablative treatments. 14 Here, we demonstrate that oral WR-2721 is an effective radioprotector 15 against otherwise lethal doses of radiation directed to the upper abdomen. 16
Furthermore, we demonstrate that the drug is well-tolerated and accumulates its 17 active metabolite, WR-1065 in significantly higher levels in the GI tract compared 18 to the serum, liver or even spontaneous pancreatic tumors. 19
Results 1

Oral WR-2721 promotes intestinal crypt survival after irradiation 2
Systemic dosing of WR-2721 by intraperitoneal (IP) injection has already 3 been shown to be effective at radioprotecting the gut of C3Hf/KamLaw mice 4 receiving whole body irradiation 11,12 , but we wanted to determine if oral (PO) 5 administration of WR-2721 would be similarly efficacious. We tested a range of 6 doses of oral WR-2721 from 0 to 1000mg/kg, followed either 15 or 30 minutes 7 after by a morbid dose of whole body irradiation (WBI). All mice were then 8 subjected to a microcolony assay, which is considered the gold standard assay 9
for demonstrating an effect of an intervention on regenerating intestinal crypts 10 after a cytotoxic insult 13 . Indeed, compared to vehicle controls, oral WR-2721 11 improved crypt survival in the duodenum when administered at either 15 or 30 12 min prior to WBI ( Figures 1A and 1B) . Similarly, oral WR-2721 also promoted 13 crypt survival in the jejunum at both 15 min ( Figure 1C ) and 30 min ( Figure 1D ) 14 after drug treatment. Oral WR-2721 protected the duodenum and jejunum at all 15 doses and timepoints compared to PBS controls except the lowest dose in the 16 duodenum at 15 min. We performed a more extended dose response in the 17 jejunum for WR-2721 given 30 min prior to 12Gy of WBI, and concluded that 18 radiation protection was likely maximized at 500mg/kg, with no further benefit 19 conferred by doubling the dose to 1000mg/kg ( Figure 1D ). There did not appear 20 to be benefit of one time point over the other in these studies. Representative 21 H&E stained jejunal sections from this study are shown in figure 1E . 22
Orally administered WR-2721 is better tolerated than intraperitoneal WR-1 2721 2 Severe nausea is a common and worrisome side effect of systemic WR-3 2721, and we were concerned that oral administration of the drug might 4 exacerbate this side effect. Although mice do not produce an emetic response to 5 noxious stimuli 14 , nausea is manifested as a decrease in body weight and food 6 intake. Thus, we closely monitored body weight and food consumption as a 7 model of nausea in mice. Based on the results of the microcolony assay ( Figure  8 1), we used 500mg/kg as the dose for toxicity testing. Mice were treated daily for 9 5 consecutive days with vehicle or WR-2721 administered IP or PO, and body 10 weight and food consumption were monitored daily ( Figure 2A and 2B, 11 respectively). There was only one vehicle control group that was subjected to 12 both gavage and intraperitoneal injections to more stringently control for the 13 stress of drug administration from either IP or PO route. Despite this intensive 14 intervention, the vehicle control animals maintained their initial bodyweight and 15 food consumption throughout the study (Figure 2A and 2B). Mice receiving 16 intraperitoneal WR-2721 at 500mg/kg, however, exhibited a dramatic decrease in 17 food consumption and body weight, requiring euthanasia by day 4 (Figure 2A  18 and 2B). In contradistinction, mice receiving oral WR-2721 had a modest initial 19 decrease in body weight and food consumption, but rapidly regained body weight 20 with a complete recovery within 2 days of stopping treatment (Figure 2A and 2B). 21
These data suggest that PO administration of WR-2721 is better tolerated than 22 systemic administration and moreover, 500mg/kg orally is a feasible dose for 1 short-term radioprotection. 2
WR-2721 protects against high-dose fractionated radiation 3
In order to ablate pancreatic cancer with ionizing radiation, radioprotection 4 of nearby duodenum and jejunum is required. We reasoned that orally 5 administered WR-2721 would be directly activated in the intestine as radiation is 6
given to maximize efficacy without systemic absorption of the drug. We modeled 7 the transit time of oral WR-2721 with a bolus of methylene blue and assessed the 8 progression of the dye front through the GI tract at 5-min intervals ( Figure S1 ). 9
We found that methylene blue reached the duodenum in 10 min and was in the 10 jejunum by 15-30 min ( Figure S1 ). Notably, within 30 min, the dye had not 11 reached the cecum or large intestine. Thus, we reasoned that oral gavage of 12 WR-2721 25 min prior to irradiation would be used in future radioprotection 13 studies. 14 Stereotactic body radiotherapy (SBRT) can deliver higher and more 15 conformal radiation doses to a smaller volume over a course of 1-5 treatments 16 with the use of advanced image guidance. SBRT, however, is still constrained 17 by the anatomy of the pancreas, where pancreatic tumors often abut or invade 18 the nearby duodenum and jejunum. We designed an SBRT treatment that used 19 10mm radiation fields that could be used to treat pancreatic cancer in mice 20 ( Figure 3A ). We correlated the radiological images with gross anatomy after 21 methylene blue gavage to determine that even in this focused radiation field that 22 a high dose to affect the entire pancreas, duodenum, and jejunum, along with a 23 portion of the gastric antrum and the left lobe of the liver which are anterior to the 1 pancreas ( Figure 3B ). 2
We performed a standard radiation dose escalation study to determine the 3 LD50/10 (dose required to produce 50% lethality in 10 days or less) for this 4 model of focused radiation 15 . Daily fractions ranged from 10 to 13Gy per fraction, 5 and were given daily over 5 consecutive days. We found that 13Gy x 5 (65Gy, 6 D2EQ=124.6Gy) led to 100% death in 10 days after treatment, and 10Gy x 5 7 (50Gy, D2EQ=83.3Gy) exhibited 100% survival at 30 days post-treatment ( Figure  8 3C). All other doses showed an intermediate phenotype, with a 20% 30-day 9 survival at 12Gy x 5 (60Gy; D2EQ=110Gy) and a 60% 30-day survival of the 10 cohort that received 11Gy x 5 (55Gy, D2EQ=96.3Gy). 11
We hypothesized that the maximal benefit of radioprotection would likely 12 occur between 12 and 13Gy at 12.5Gy x 5 fractions (62.5 Gy; D2Eq=117.2Gy). 13
Thus, a new cohort of mice was treated with 5 daily fractions of 12.5Gy to the 14 upper abdomen in a similar field as shown in Figure 3A , with radioprotection 15 afforded by orally administered WR-2721 or vehicle control 25 minutes prior to 16 each radiation treatment. Remarkably, 100% of mice that received oral WR-17 2721 lived beyond 30 days, while all vehicle controls died in fewer than 10 days 18 Figure 3D , log rank p=0.0035). 19
Selective enrichment of WR-1065 within intestines from oral WR-2721 20
We hypothesized that oral WR-2721 acts via localized conversion to WR-21 1065 by intestinal alkaline phosphatases in the duodenum and jejunum. This 22 would concentrate the active metabolite WR-1065 only in the dose-limiting areas 23 of the intestine during radiation, and possibly reduce off-target effects. To 1 understand if this was indeed the physiologic mechanism of action, we 2 developed a mass spectrometry assay to measure the concentrations of WR-3 1065, the active metabolite of WR-2721, in both serum and tissues. We first 4 assessed the pharmacokinetics of WR-1065 appearance in the plasma and other 5 tissues after oral gavage with 500mg/kg or IP injection with 250mg/kg of WR-6 2721 in C57BL/6 mice (see schema in Figure 4A ). Serum and tissues were 7 collected 25 min after gavage, which approximates the distribution of WR-1065 in 8 tissues at the time of radiation ( Figure 3C We demonstrate that orally administered WR-2721 is well tolerated, and 5 radioprotects the intestinal tract from ablative doses of fractionated radiation. 6
Here, we utilize the natural gradient of intestinal alkaline phosphatases within the 7 duodenum and jejunum to rapidly WR-2721 to the radioprotective WR-1065 8 within in the gut, while limiting exposure to the rest of the body where protection 9
is not needed, and may be counterproductive. This is most readily illustrated in 10 our experiments with genetically engineered mice that show with a sensitive 11 mass spectrometry technique that WR-1065 accumulates significantly higher 12 concentrations in intestines, but not within pancreatic tumors. 13
The route of administration matters greatly depending on which tissues 14 should be protected from radiation, but currently we are limited to intravenous 15 injections of amifostine. For salivary gland protection, intravenous administration 16 is logical since this allows the protective metabolite WR-1065 to accumulate 17 systemically then rapidly enter these organs prior to radiation. There has never 18 been demonstration of tumor radioprotection, but nevertheless has remained a 19 theoretical concern of systemic administration. We demonstrate this point here 20
showing that intraperitoneal administration causes rapid equilibration of WR-1065 21 across normal tissues and tumors (Figure 4) . Moreover, aberrant activation of 22 amifostine in the endothelial compartments 9 , may be partially responsible for 23 many of the unpleasant side effects of systemic administration, such as nausea 1 and hypotension. 2
Alternative routes for WR-2721 administration have been tested previously 3 with largely negative results. For instance, endorectal infusion of amifostine was 4 found to improve toxicity profiles after pelvic radiation in Phase I studies 18,19 , but 5 failed to meet endpoints in a larger randomized study 20 . These may be due, in 6 part, to reliance on the ubiquitous and non-specific alkaline phosphatases 7 present in most cells. Moreover, the rectal mucosa has a thick mucus lining and 8 expresses low levels of intestinal alkaline phosphatase 21 , which is required to 9 activate WR-2721 22 . 10
The advantage of using oral WR-2721 is that it is already an FDA 11 approved drug, and the pathway to repurposing this drug as an orally activated 12 agent may be shorter than developing a new chemical variant 23 or trying to win 13 approval of enteric or nanoparticle formulations of WR-1065 24-26 . Thus, we view 14 these studies as a proof of principle that WR-2721, or similar thiophosphate 15 prodrugs, could be used to selectively target the intestine for radioprotection 16 while limiting exposure to other normal tissues thereby decreasing the severity of 17 the side effects as we demonstrate in this study (Figure 2) . 18
Pancreatic cancer requires a biologically equivalent dose of more than 19 77Gy to have a clinical benefit 27 . Currently, this is not attainable for most 20 pancreatic tumors unless they are in a location that is at least 1cm away from 21 bowel 2 . In addition to the possible use of oral WR-2721 for improving the 22 outcomes for pancreatic cancer patients, a similar strategy could be explored for 23 others abdominal or pelvic cancers that cannot be treated definitively with 1 radiation due to GI toxicity, such as hepatobiliary tumors, retroperitoneal 2 sarcomas, or even metastatic disease within the abdomen. 3 4
Materials and methods 1
Mice 2 C57BL/6JLaw and C3Hf/KamLaw mice were purchased from the Department of 3 Experimental Radiation Oncology's specific pathogen free animal facility at the 4 MD Anderson Cancer Center. Kras LSL/+ ; Trp53 FL/+ ; Ptf1a Cre/+ mice were 5 backcrossed to a pure C57BL/6 background over ten generations genotyped as 6 described previously 28 . All mice were maintained in accordance with the 7 Association for Assessment and Accreditation of Laboratory Animal Care and the 8 Institutional Animal Care and Use Committee guidelines. Female C3Hf/KamLaw 9 mice were used for the microcolony assay 13 and were 12-14 weeks old at the 10 start of treatment. Tumor-bearing KPC mice were used in the LC/MS-MS tissue 11 analysis of WR-1065 concentrations.
The remaining studies use male 12 C57BL/6JLaw mice at 8 weeks of age at the start of all studies. 13
WR-2721 14
WR-2721 Trihydrate (Toronto Research Chemicals Inc; North York, Ontario, 15
Canada) was diluted in PBS (with 0.2 conversion factor to adjust for trihydrate) 16
and was administered by IP injection at 25or250 or 500mg/kg or by oral gavage 17 at doses from5from 150 to 1000 mg/kg in a volume of 0.1ml. 18
Irradiation 19
For survival studies, SBRT was given for 5 consecutive days 25min after 20 administration of vehicle or WR-2721 using the XRAD 225Cx small animal 21 irradiator (Precision X-Ray; North Branford, CT) fitted with a conformal collimator 22 to produce a circular 10mm diameter radiation field. Mice were anesthetized with 1 isoflurane gas for CT imaging and irradiation. Each mouse was imaged using 2 the XRAD 225Cx cone beam CT prior to irradiation in order to align the radiation 3 field so that the cranial edge of the field was located 5mm below the diaphragm 4 at the isocenter of the mouse. This field exposed the pancreas, duodenum, 5 jejunum and liver to radiation. Radiation was administered AP/PA. 6
For the microcolony assay, a single dose of 12Gy whole body irradiation 7 was administered 15min or 30min after WR-2721 treatment using a Pantak 300 8
x-ray unit (Pantak; East Haven, CT), with 300kVp X-rays at a dose rate of 1.84 9 Gy/min. Un-anesthetized mice were loosely restrained in a well ventilated 15 x 10 15 x 2cm Lucite box during WBI. 11
Methylene blue gut assay 12
In order to determine the rate at which oral solutions such as WR-2721 traverse 13
the digestive tract of 8-week old C57BL/6 mice following oral gavage, a 1% (w/v) 14 solution of methylene blue in PBS was gavaged in a total volume of 0.1ml. Mice 15 were then euthanized at 5, 10, 15, 25 and 30min after the dye administration and 16 the progress of the methylene blue stain through the intestines was examined. 17
Mice were anesthetized with isoflurane 8 min prior to euthanasia following the 18 same procedure used prior to irradiation (8 min at 3% isoflurane and oxygen flow 19 rate of 2 L/min) to account for any potential changes it might have on GI transit 20 time. Methylene blue dye progress was examined in situ for comparison with the 21 location of our standard radiation field and then the intestine was excised so that 22 distance traveled could be determined. 23
Survival studies 1
Mice were treated with WR-2721 or vehicle by IP injection or oral gavage 2 followed by SBRT and monitored on a daily basis. Once mice became moribund 3 (exhibited ruffled fur, hunched posture, persistent diarrhea and greater than 20% 4 weight loss) they were euthanized. Time to euthanasia and percent survival 5 were assessed. 6
Microcolony assay 7
Viable jejunal crypts were quantified following a single dose of 12Gy WBI +/-a 8 single oral dose of WR-2721 given at 15 min or 30 min prior to radiation using the 9 microcolony assay 13 . Mice were euthanized 3 days and 14 hours after receiving 10 WBI, and segments of jejunum and duodenum were resected and fixed in 10% 11 neutral buffered formalin. Tissue was then embedded in paraffin, and four 12 transverse slices of jejunum and duodenum were stained with hematoxylin and 13 eosin per mouse. The number of regenerating crypts per transverse section was 14 scored microscopically and averaged over the 4 sections per animal for each 15 tissue type. All slides were scored by a single observer blinded to treatment 16 group. 17
LC/MS-MS analysis of WR-1065 tissue concentrations 18
Mice were treated with either 500mg/kg of WR-2721 by oral gavage, or 19 250 mg/kg by IP injection. After 17min had elapsed, the mice were anesthetized 20 with isoflurane gas (3% isoflurane, oxygen flow rate of 2L/min). After 8 min of 21 anesthesia, whole blood and tissues were collected. The total amount of time 22 between treatment and tissue collection was 25 min. 23
While under isoflurane anesthesia, the whole blood sample was collected 1 via cardiac puncture and was immediately transferred to a BD Microtainer® blood 2 collection tube containing K 2 -EDTA (Becton Dickinson; Franklin Lakes, NJ). The 3 K 2 -EDTA whole blood was then processed to plasma by centrifugation at 3,000g 4 for 4 min. After processing, a volume of the plasma supernatant (typically 200 µL) 5 was removed and immediately transferred to a fresh 1.4 mL Matrix polypropylene 6 (PP) tube (Thermo Fisher Scientific; Waltham, MA) containing a 50 µL aliquot of 7 10% trichloroacetic acid (TCA). After vortexing, the TCA-treated plasma samples 8 were stored on ice for transport from the vivarium to the laboratory for further 9 processing. The TCA-treated plasma samples were then centrifuged at 17,000g 10 for 5 min, and the supernatant was transferred to a fresh 1.4 mL Matrix tube, and 11 the samples were either extracted and analyzed immediately or capped for -80 12 °C storage until analysis. 13
After blood collection, the mouse was euthanized, the duodenum, 14 jejunum, liver, and tumor tissue samples were collected, and each tissue sample 15 was placed into individually labeled PP tubes and weighed. After weighing, an 16 aliquot of 2% TCA was added to each tube (the tissue density at 200 mg tissue 17 per mL of solution or below for all samples), and the tissues were homogenized 18 using a Polytron PT 1200 E hand-held homogenizer. After homogenization, the 19 TCA-treated tissue samples were stored on ice for transport from the vivarium to 20 the laboratory for further processing. The TCA-treated tissue samples were then 21 centrifuged at 4,500g for 5 min, and the supernatant was transferred to a fresh 2 22 mL Simport tube (Simport; Montreal, Canada), and the samples were either 1 extracted and analyzed immediately or capped for -80 °C storage until analysis. Intermediate-concentration solutions were prepared at 100 µg/mL for each 9 compound using consistent solvents mixed 1:1 with acetonitrile. 10 11
Preparation of WR-1065 calibration standards. 12
Two separate sets of WR-1065 calibration standards (Calibrators) were 13 prepared by serial dilution using either 2% TCA-treated plasma matrix or 2% 14 TCA-treated duodenal matrix as the diluent. After the preparation of each 15
Calibrator in each set, the standard was vortexed for a minimum of 30 s to 16 ensure proper mixing prior to performing the subsequent dilution. The Calibrators 17 were prepared at 1.00, 2.00, 10.0, 100, 250, 500, 900, and 1,000 ng/mL in each 18 matrix. The Calibrators were prepared and stored individually in labeled 2 mL 19 Simport tubes, were maintained ice-cold while in use, and stored at -80 °C when 20 not in use. 21
Extraction method for the 2% TCA-treated plasma and tissue samples. 22
All calibrators, 2% TCA blank plasma matrix and study samples were 1 thawed and stored on ice for the duration of the extraction procedure. A 2 µL 2 aliquot of an ice-cold aqueous 10% TCA (w/v) solution was added to each 1.4 3 mL PP Matrix sample tube. A 10 µL aliquot of each Calibrator, blank sample 4 matrix, and study sample was added to the appropriate tube. Then, a 90 µL 5 aliquot of ice-cold acetonitrile was added to each tube, and the samples were 6 capped and vortexed for 2 min. Finally, the samples were centrifuged at 17,000g 7 for 5 min, and then the supernatant was transferred to PP injection vials for 8 sample analysis. A typical injection volume for analysis was 10 µL. 9
The extraction process for the 2% TCA-treated tissue samples was similar 10 to the plasma extraction procedure described above, with the following exception 11 -the tissue samples do not receive a 2 µL aliquot of an ice-cold aqueous 10% 12 TCA solution. After performing the protein precipitation and centrifugation step 13 The chromatographic method included a column temperature of 40°C, 4 autosampler tray chilled to 4°C, a mobile phase flow rate of 300 µL/min, and a 5 gradient elution program specified as follows: 0-5 min, 50% MPB; 5-5.5 min, 50-6 80% MPB; 5.5-11 min, 80% MPB; 11-11.5 min, 80-50% MPB; 11.5-15 min, 50% 7 MPB. The overall cycle time of the chromatographic gradient program was 15.5 8 minutes per sample. The blank plasma samples after the highest Calibrator 9
(1,000 ng/mL) was free from carryover when a solution of 1:1 acetonitrile:water 10 with 0.1% formic acid was used as the needlewash. 11
The TSQ Quantiva was operated in positive ion mode and had the 12 
Statistical analyses 20
Log-Rank analysis was used for survival studies and median survival was 21 determined with 95% confidence interval (CI). Two tailed t-tests with unequal 22 variance were used to compare PO vs. IP plasma and tissue concentrations of 1 WR-1065. Values less than 0.05 were considered significant. 2 
Figure Legends
